Drug intelligence / Profile preview

18F-FC211

Development stage: Preclinical
Lead developer: FutureChem
Modality: Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

18F-FC211 is a fluorine-18 labeled small molecule radiopharmaceutical developed by FutureChem Pharma for the positron emission tomography (PET) imaging of tau protein pathology. Tau protein aggregates are a hallmark of neurodegenerative diseases, particularly Alzheimer's disease, and their distribution in the brain correlates strongly with cognitive decline. As a diagnostic tracer, 18F-FC211 is designed to bind specifically to tau neurofibrillary tangles, allowing for the non-invasive visualization and quantification of tau burden in the central nervous system. The program is currently in the preclinical stage of development.

Other names: [18F]FC211

Targets

MAPT (Microtubule-associated protein tau)

Beyond the preview

Go deeper on 18F-FC211.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 18F-FC211.

Explore the full profile